Prognostic significance of VEGF, VEGF receptors, and microvessel density in diffuse large B cell lymphoma treated with anthracycline-based chemotherapy

[1]  J. Dorsman,et al.  Cisplatin and doxorubicin repress Vascular Endothelial Growth Factor expression and differentially down-regulate Hypoxia-inducible Factor I activity in human ovarian cancer cells. , 2007, Biochemical pharmacology.

[2]  Amy V Kapp,et al.  Microvessel density and expression of vascular endothelial growth factor and its receptors in diffuse large B-cell lymphoma subtypes. , 2007, The American journal of pathology.

[3]  K. Podar,et al.  Inhibition of VEGF Signaling Pathways in Multiple Myeloma and Other Malignancies , 2007, Cell cycle.

[4]  J. Verweij,et al.  The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. , 2006, European journal of cancer.

[5]  A. Giatromanolaki,et al.  Angiogenesis in Colorectal Cancer: Prognostic and Therapeutic Implications , 2006, American journal of clinical oncology.

[6]  S. Fox,et al.  Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  L. Claesson‐Welsh,et al.  VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.

[8]  I. Lossos,et al.  Prognostic biomarkers in diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Gordon,et al.  Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis , 2006, Leukemia & lymphoma.

[10]  J. Raemaekers,et al.  Angiogenesis in malignant lymphoma , 2005, Current opinion in oncology.

[11]  H. Johnsen,et al.  Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin’s lymphoma , 2005, Annals of Hematology.

[12]  K. Podar,et al.  The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. , 2005, Blood.

[13]  Yasodha Natkunam,et al.  Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. , 2004, Blood.

[14]  J. Raemaekers,et al.  Increased vascularization predicts favorable outcome in follicular lymphoma. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  J. Teruya-Feldstein,et al.  Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo. , 2004, Blood.

[16]  K. Kihara,et al.  Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids , 2004, Molecular and Cellular Endocrinology.

[17]  Santhosh K. P. Kumar,et al.  Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy , 2004, Bone Marrow Transplantation.

[18]  H. Joensuu,et al.  Elevated serum endostatin is associated with poor outcome in patients with non‐Hodgkin lymphoma , 2003, Cancer.

[19]  K. Norrby,et al.  Tumour‐type‐specific capillary endothelial cell stainability in malignant B‐cell lymphomas using antibodies against CD31, CD34 and Factor VIII , 2003, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[20]  N. Ferrara,et al.  VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism , 2002, Nature.

[21]  Lena Claesson-Welsh,et al.  VEGF Receptor Signal Transduction , 2001, Science's STKE.

[22]  I. Avramis,et al.  Taxotere and vincristine inhibit the secretion of the angiogenesis inducing vascular endothelial growth factor (VEGF) by wild-type and drug-resistant human leukemia T-cell lines. , 2001, Anticancer research.

[23]  H. Joensuu,et al.  Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients. , 2000, Blood.

[24]  O. Bairey,et al.  Microvessel density in chemosensitive and chemoresistant diffuse large B-cell lymphomas , 2000, Medical oncology.

[25]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Machein,et al.  Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells , 1999, Neuropathology and applied neurobiology.

[27]  T. Noda,et al.  Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  M. Volm,et al.  Angiogenic growth factors and their receptors in non-small cell lung carcinomas and their relationships to drug response in vitro. , 1997, Anticancer research.

[29]  R. Kurzrock,et al.  Serum interleukin-6 levels correlate with prognosis in diffuse large-cell lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Ribatti,et al.  Bone marrow angiogenesis and progression in multiple myeloma , 1994, British journal of haematology.

[31]  J. Blay,et al.  Serum interleukin-10 in non-Hodgkin's lymphoma: a prognostic factor. , 1993, Blood.

[32]  J. Folkman,et al.  Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. , 1991, The New England journal of medicine.